Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. 2025;88:559-563.
APA
Roviello G, Antonuzzo L (2026). Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. 2025;88:559-563.. European urology, 89(3), e73. https://doi.org/10.1016/j.eururo.2025.08.033
MLA
Roviello G, et al.. "Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. 2025;88:559-563.." European urology, vol. 89, no. 3, 2026, pp. e73.
PMID
41016909
같은 제1저자의 인용 많은 논문 (3)
- From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer.
- Adjuvant immunotherapy in high-risk renal cell carcinoma: Indications, limitations, and perspectives. A consensus statement from the GIOTTO uro-oncology group.
- Re: Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al. Systemic Therapy in Patients with Metastatic Castration-resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol 2025;43:2311-34.